 |
Available data about
compatibility for recommended indications and actives: |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Care of problem dry
skin
|
|
|
 |
|
|
|
|
|
|
|
|
Active ingredient
|
|
 |
|
Recommended indications |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salicylic Acid |
|
|
Scaly dermatoses |
|
|
|
|
|
up to 3,0% |
|
|
up to 3,0% |
|
|
|
|
|
|
|
|
|
|
Clobetasol-17-propionate |
|
|
Dermatoses requiring steroids, e.g. eczema
|
|
|
|
|
|
0,05% |
|
|
0,05% |
|
|
|
|
|
|
|
|
|
|
Triamcinolone acetonide |
|
|
|
|
|
|
|
|
0,1% |
|
|
0,1% |
|
|
|
|
|
|
|
|
|
|
Hydrocortisone acetate |
|
|
|
|
|
|
|
|
1,0% |
|
|
1,0% |
|
|
|
|
|
|
|
|
|
|
Urea |
|
|
Loss of moisture, extremely dry skin |
|
|
5,0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Polidocanol |
|
|
Itching dermatoses |
|
|
5,0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Urea and polidocanol |
|
|
Itching dermatoses, Pruritus senilis |
|
|
5,0% + 5,0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Betamethasone valerate |
|
|
Eczema, dermatoses requiring steroids |
|
|
0,1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dexpanthenol |
|
|
Wound healing |
|
|
3,0% |
|
|
|
|
|
|
|
|
|
|
|
|
Note: The tested shelf-life (chemical
and formula stability) of the active ingredient and preparation is
6 weeks at room temperature. |
|
top
of page 
|
Care of problem dry
skin
|
|
|
|
|
|
|
|
|
|
Active ingredient
|
|
|
|
Recommended indications
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benzoyl peroxide |
|
|
Acne in dry skin |
|
|
up to 10% |
|
|
up to 10% |
|
|
|
|
|
|
|
|
|
Bufexamac |
|
|
Atopic eczema |
|
|
5,0% |
|
|
5,0% |
|
|
|
|
|
|
|
|
|
Clotrimazole |
|
|
Mycoses, seborrheic dermatitis |
|
|
2,0% |
|
|
2,0% |
|
|
|
|
|
|
|
|
|
Dexamethasone |
|
|
Steroid-responsive dermatoses such as eczema, psoriasis |
|
|
0,1% |
|
|
– |
|
|
|
|
|
|
|
|
|
Dexpanthenol |
|
|
Severely afflicted dry skin, promotes wound healing |
|
|
5,0% |
|
|
5,0% |
|
|
|
|
|
|
|
|
|
Erythromycin |
|
|
Superinfected eczemas, acne in dry skin |
|
|
4,0% |
|
|
– |
|
|
|
|
|
|
|
|
|
Hydrocortisone |
|
|
Steroid-responsive dermatoses |
|
|
2,0% |
|
|
2,0% |
|
|
|
|
|
|
|
|
|
Lactic acid |
|
|
Scaly dermatoses not on facial or intertriginous
areas |
|
|
up to 10,0% |
|
|
2,0% |
|
|
|
|
|
|
|
|
|
Evening primrose oil |
|
|
Dermatoses associated with dry skin (eczema, neurodermatitis,
psoriasis) |
|
|
up to 10,0% |
|
|
– |
|
|
|
|
|
|
|
|
|
Salicylic acid |
|
|
Psoriasis, ichthyosis, cornification disorders |
|
|
– |
|
|
5,0% |
|
|
|
|
|
|
|
|
|
Coal tar |
|
|
Chronic eczema, chronic atopic dermatitis, psoriasis
vulgaris |
|
|
up to 10,0% |
|
|
up to 10,0% |
|
|
|
|
|
|
|
|
|
Tetracycline-HCl |
|
|
Superinfected dermatoses |
|
|
up to 5,0% |
|
|
– |
|
|
|
|
|
|
|
|
|
Triamcinolone acetonide |
|
|
Eczema, inflammatory dermatoses |
|
|
0,5% |
|
|
0,5% |
|
|
|
|
|
|
|
|
|
Zinc oxide |
|
|
Inflammatory dermatoses |
|
|
up to 5,0% |
|
|
up to 10,0% |
|
|
|
|
|
|
|
|
|
Zinc sulphate |
|
|
Astringent |
|
|
1,0% |
|
|
1,0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Low concentration Eucerin® Urea
Preparations (3-5%) are primarily suitable for the treatment of
constitutionally, environmentally or occupationally induced types
of problem dry skin. Also for supportive therapeutic care of all dermatoses
such as ichthyosis, psoriasis, eczema, neurodermatitis. Not to be
applied to open wounds as stinging may occur.
Eucerin® 5% Urea Cream: especially suitable for hands,
elbows, knees, and feet.
Note: The tested shelf-life (chemical and formula stability)
of the active ingredient and preparation is 6 weeks at room temperature.
|
|
top
of page
|
|
|
|
|
|
|
|
|
|
|
Active ingredient
|
|
|
|
Recommended indications
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benzoyl Peroxide |
|
|
Acne vulgaris (on the body) |
|
|
up to 10,0% |
|
|
– |
|
|
|
|
|
|
|
|
|
Bufexamac |
|
|
Atopic dermatitis |
|
|
5,0% |
|
|
5,0% |
|
|
|
|
|
|
|
|
|
Clotrimazole |
|
|
Mycoses, seborrheic dermatitis (for application over
large areas) |
|
|
2,0% |
|
|
2,0% |
|
|
|
|
|
|
|
|
|
Dexamethasone |
|
|
Steroid-responsive dermatoses such as eczema, psoriasis |
|
|
up to 0,1% |
|
|
– |
|
|
|
|
|
|
|
|
|
Dexpanthenol |
|
|
Wound healing |
|
|
up to 5,0% |
|
|
up to 5,0% |
|
|
|
|
|
|
|
|
|
|
Hydrocortisone |
|
|
Steroid-responsive dermatoses |
|
|
2,0% |
|
|
up to 2,0% |
|
|
|
|
|
|
|
|
|
Lactic acid |
|
|
Scaly dermatoses not in facial and intertriginous
areas |
|
|
2,0% |
|
|
2,0% |
|
|
|
|
|
|
|
|
|
Evening primrose oil |
|
|
Dermatoses associated with dry skin (eczema, neurodermatitis,
psoriasis) |
|
|
up to 10,0% |
|
|
up to 5,0% |
|
|
|
|
|
|
|
|
|
Salicylic acid |
|
|
Scaly dermatoses, not on large areas or prolonged
use* |
|
|
5,0% |
|
|
5,0% |
|
|
|
|
|
|
|
|
|
Coal tar |
|
|
Chronic eczema, chronic atopic dermatitis, psoriasis
vulgaris |
|
|
– |
|
|
up to 10,0% |
|
|
|
|
|
|
|
|
|
Coal tar solution |
|
|
Chronic eczema, chronic atopic dermatitis, psoriasis
vulgaris |
|
|
up to 10,0% |
|
|
– |
|
|
|
|
|
|
|
|
|
Triamcinolone acetonide |
|
|
Steroid-responsive dermatoses such as eczema, psoriasis |
|
|
up to 0,5% |
|
|
up to 0,5% |
|
|
|
|
|
|
|
|
|
Zinc oxide |
|
|
Inflammatory dermatoses |
|
|
up to 5,0% |
|
|
up to 10,0% |
|
|
|
|
|
|
|
|
|
Zinc sulphate |
|
|
Astringent |
|
|
– |
|
|
1,0% |
|
|
|
|
|
|
|
* Strictly contraindicated in pregnancy
Note: The tested shelf-life (chemical and formula stability)
of the active ingredient and preparation is 6 weeks at room temperature. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Eucerin® 10% Urea Ointment
(active ingredient: urea)
Indications: For the treatment of dry skin, e.g. for neurodermatitis
or aged skin Contraindications: Do not use if there is a known
sensitivity to this product, or for the treatment of inflammatory
skin conditions and do not apply to large areas in patients with impaired
renal function. Also do not use to treat children, as there is insufficient
research into the use of this medication in this age group. Side
effects: Skin irritation is possible when used to treat acute
inflammatory skin conditions. Interactions: The release of
active ingredients from other externally applied medications and their
skin permeability may be increased in the presence of urea. This is
known to occur with corticosteroids, dithranol and fluorouracil. |
|
top
of page
|
Care
of atopic dry skin
|
|
|
|
|
|
|
|
|
|
|
|
Active ingredient
|
|
|
|
IRecommended indications
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bufexamac |
|
|
Atopic dermatitis |
|
|
5,0% |
|
|
5,0% |
|
|
5,0% |
|
|
|
|
|
|
|
|
|
|
Chlorhexidine digluconate |
|
|
Superinfected eczema |
|
|
– |
|
|
– |
|
|
0,5% |
|
|
|
|
|
|
|
|
|
|
Clotrimazole |
|
|
Mycoses (for application over large areas) seborrheic
eczema |
|
|
2,0% |
|
|
2,0% |
|
|
2,0% |
|
|
|
|
|
|
|
|
|
|
Dexpanthenol |
|
|
Wound healing |
|
|
up to 5,0% |
|
|
up to 5,0% |
|
|
up to 5,0% |
|
|
|
|
|
|
|
|
|
|
Erythromycin |
|
|
Superinfected eczema, acne on dry skin |
|
|
– |
|
|
– |
|
|
4,0% |
|
|
|
|
|
|
|
|
|
|
Glycerin |
|
|
Very dry atopic skin |
|
|
10,0% |
|
|
10,0% |
|
|
10,0% |
|
|
|
|
|
|
|
|
|
|
Hydrocortisone |
|
|
Steroid-responsive dermatoses |
|
|
up to 2,0% |
|
|
up to 2,0% |
|
|
up to 2,0% |
|
|
|
|
|
|
|
|
|
|
Nystatin |
|
|
Mycoses, nappy-area mycoses |
|
|
– |
|
|
2,0% |
|
|
2,0% |
|
|
|
|
|
|
|
|
|
|
Polidocanol |
|
|
Itching dermatoses |
|
|
– |
|
|
– |
|
|
5,0% |
|
|
|
|
|
|
|
|
|
|
Coal tar solution |
|
|
Chronic eczema, chronic atopic dermatoses, psoriasis
vulgaris |
|
|
2,0% |
|
|
up to 10,0% |
|
|
up to 10,0% |
|
|
|
|
|
|
|
|
|
|
Urea |
|
|
Extremely dry skin |
|
|
– |
|
|
up to 10,0% |
|
|
up to 10,0% |
|
|
|
|
|
|
|
|
|
|
Zinc oxide |
|
|
Inflammatory dermatoses |
|
|
up to 5,0% |
|
|
up to 5,0% |
|
|
up to 5,0% |
|
|
|
|
|
|
Note: The tested shelf-life (chemical
and formula stability) of the active ingredient and preparation is
6 weeks at room temperature. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Eucerin® Omega Fatty Acid
topical preparations for supportive therapeutic care of atopic dry
skin, nappy-rash dermatitis and dermatoses associated with a disturbed
barrier function, such as psoriasis, ichthyosis and neurodermatitis,
especially at the end of an active phase and during the latent phase.
They are also suitable for therapy-induced dry skin (chemotherapy,
dialysis).
Eucerin® 12% Omega Fatty Acid Cream and Eucerin®
12% Omega Fatty Acid Lotion: Preventative skin protection, especially
in occupations that deal with liquids.
Eucerin® 20% Omega Fatty Acid Ointment: In cold, dry weather
it is also suitable as protection against the cold air (children and
adults with neurodermatitis). In cases of infantile eczema (seborrheic
dermatitis in infancy) use in the nappy-area with every nappy change. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Eucerin® Omega Fatty Acid Oil
Bath: Indications: Supportive treatment of skin conditions (dermatoses)
with dry, itchy skin, e.g. endogenous eczema (neurodermatitis), psoriasis,
nappy rash, wash dermatitis. Contraindications: Not to be used
in acute pustular psoriasis or if there is hypersensitivity to any
of the ingredients. In the case of extensive skin injuries, acute
skin diseases, severe febrile and infectious diseases, heart failure
and hypertension, full baths (irrespective of the ingredients) should
be taken only after consulting a physician. Side effects:
Rarely, skin intolerance reactions. Interactions: Simultaneous
use of soaps/syndets neutralises the effect of the oil bath. Warnings:
Keep oil baths out of contact with the eyes. If accidental contact
occurs, irrigate immediately with plenty of water. Increased risk
of slipping because of the oilfilm on the skin and in the bathtub. |
|
|
